Lung Cancer Therapy

Researchers developed a highly sensitive, analytic, quantitative immunofluorescence assay that may enable more patients with lung cancer to benefit from an approved targeted therapy.

Results of the GEMSTONE-301 study showed that sugemalimab was well tolerated and effective in patients with stage III non-small cell lung cancer. It was the top story in hematology/oncology last week.